# OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy

> **NCT02058017** · PHASE1 · TERMINATED · sponsor: **National University Hospital, Singapore** · enrollment: 9 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** OPB-51602

## Key facts

- **NCT ID:** NCT02058017
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lactic and metabolic acidosis of OPB-51602 is not tolerable
- **Last updated:** 2015-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058017, "OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02058017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*